AIFF
Firefly Neuroscience, Inc.1.4100
-0.0600-4.08%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
19.03MP/E (TTM)
-Basic EPS (TTM)
-2.26Dividend Yield
0%Recent Filings
8-K
ATM for $7.4M shares
Firefly Neuroscience inked an ATM agreement on February 3, 2026, with Konik Capital Partners to sell up to $7,434,266 in common stock opportunistically on Nasdaq. Proceeds target working capital. Separately, CTO Gil Issachar's bonus shifted to discretionary up to one month's salary effective January 1, 2026, while settling 157,500 NIS in prior arrears over 24 months. Flexible cash access, yet no sales obligation.
8-K
Warrants exchanged at $0.50
10-Q
Q3 FY2025 results
Firefly Neuroscience ramped revenue to $388 thousand in Q3 ended September 30, 2025, up 1,076% y/y from $33 thousand, fueled by the Evoke acquisition, while gross profit hit $146 thousand. Operating loss narrowed to $2.7M from $4.3M y/y as R&D and G&A expenses dropped over 30%, despite a $152 thousand intangible impairment from strategic shifts. Cash climbed to $4.3M, bolstered by $11.4M in financing; operating cash burn was $6.4M YTD. Evoke closed April 30, 2025 for $3M cash plus 857K shares ($2.7M fair value), recognizing $5.2M goodwill and $700K developed technology (9-year life). Shares outstanding ballooned to 13.5M. Evoke expands brain electrical activity measurement capacity.
8-K
Stockholders approve key governance
Firefly Neuroscience stockholders approved electing Brian Posner and Stella Vnook as Class II directors until 2028, ratifying Marcum Canada as auditors for 2025, and boosting the 2024 LTIP share pool by 317,820 shares with annual evergreen increases through 2035. They also greenlit hiking authorized shares from 101 million to 5.001 billion after adjourning the October 27 meeting. All passed handily. This equips Firefly for equity incentives and capital maneuvers.
8-K
Terminates ELOC, boosts CFO pay
Firefly Neuroscience terminated its $10 million equity line of credit agreement with Arena Business Solutions, effective September 11, 2025, after entering it in December 2024. Meanwhile, the board approved a salary hike for CFO Paul Krzywicki from CA$165,000 to CA$216,000 starting September 1, 2025. Termination simplifies capital access. No further impacts disclosed.
ALIT
Alight, Inc.
2.06+0.00
APYP
APPYEA, Inc.
0.01-0.00
AVAI
Avant Technologies Inc.
0.32+0.00
BFLY
Butterfly Network, Inc.
3.34+0.12
BWAY
Brainsway Ltd.
16.87-0.47
FLY
Firefly Aerospace Inc.
20.28-0.08
FYNN
Fyntechnical Innovations, Inc.
0.00+0.00
NMTC
NeuroOne Medical Technologies C
0.71+0.05
SNOW
Snowflake Inc.
220.60+5.32
WYFI
WhiteFiber, Inc.
15.08-0.13